Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01831089
Title Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors PharmaMar
Indications

head and neck cancer

breast cancer

ovarian cancer

female reproductive organ cancer

lung non-small cell carcinoma

lung small cell carcinoma

Therapies

Bevacizumab + Lurbinectedin + Paclitaxel

Lurbinectedin + Paclitaxel

Age Groups: adult | senior
Covered Countries USA | ESP


No variant requirements are available.